ImageneBio, Inc. (IMA) stock

IMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30

$3.45−0.27 (-7.26%)

Close on Nov 12, 2026Market cap $39.16MP/E –Yield –

ImageneBio r&d expenses

Research and development expenses are spending on new products and technology.

ImageneBio's R&D Expenses for the twelve months ending Sep 30, 2026 was $27.58M, down 3.6% year over year. For fiscal 2025 it was $28.53M, down 11.2% from the year before. The highest annual figure on record is $64.32M in fiscal 2022.

Annual r&d expenses

Period	Period end	Value	Change
FY2025	Dec 31, 2025	$28.53M	-11.2%
FY2024	Dec 31, 2024	$32.11M	-46.2%
FY2023	Dec 31, 2023	$59.65M	-7.3%
FY2022	Dec 31, 2022	$64.32M	+36.5%
FY2021	Dec 31, 2021	$47.11M	+5.0%
FY2020	Dec 31, 2020	$44.85M	–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q3 FY2026	Sep 30, 2026	$11.27M	-25.6%
Q2 FY2026	Jun 30, 2026	$6.67M	+18.0%
Q1 FY2026	Mar 31, 2026	$5.96M	+47.5%
Q4 FY2025	Dec 31, 2025	$3.68M	-2.2%
Q3 FY2025	Sep 30, 2025	$15.16M	+290.1%
Q2 FY2025	Jun 30, 2025	$5.65M	-42.5%
Q1 FY2025	Mar 31, 2025	$4.04M	-58.1%
Q4 FY2024	Dec 31, 2024	$3.76M	-73.7%
Q3 FY2024	Sep 30, 2024	$3.89M	-73.5%
Q2 FY2024	Jun 30, 2024	$9.83M	-35.2%
Q1 FY2024	Mar 31, 2024	$9.65M	-38.0%
Q4 FY2023	Dec 31, 2023	$14.27M	-8.7%
Q3 FY2023	Sep 30, 2023	$14.65M	-22.3%
Q2 FY2023	Jun 30, 2023	$15.17M	-2.0%
Q1 FY2023	Mar 31, 2023	$15.55M	+8.4%
Q4 FY2022	Dec 31, 2022	$15.64M	+26.8%
Q3 FY2022	Sep 30, 2022	$18.85M	+40.9%
Q2 FY2022	Jun 30, 2022	$15.49M	+36.2%
Q1 FY2022	Mar 31, 2022	$14.34M	+43.1%
Q4 FY2021	Dec 31, 2021	$12.34M	-47.3%
Q3 FY2021	Sep 30, 2021	$13.38M	+85.3%
Q2 FY2021	Jun 30, 2021	$11.37M	+79.6%
Q1 FY2021	Mar 31, 2021	$10.02M	+27.0%
Q4 FY2020	Dec 31, 2020	$23.40M	–
Q3 FY2020	Sep 30, 2020	$7.22M	–
Q2 FY2020	Jun 30, 2020	$6.33M	–
Q1 FY2020	Mar 31, 2020	$7.89M	–